is retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You might mention that, "We are concerned about stockholder value" one more time. I like the sound of it.
Endu, This article is 7 months old. Is the patient in phase 2?
We need some news that is current.
Please help me understand the Apple license. It would seem to be more valuable than Nokia's future 3G or 4G license. Yet, we are spending time and money chasing Nokia even though they are losing market share in this market to Apple. Aren't we due to renegotiate the apple licevse because of the extraordinary success of the i phone and iPad. Does anyone know anything about this? TIA
Questions for the ASM. I regret that I can't attend but would like to know:
Are there license agreement discussions with Ericsson and Motorola? Why has there not been any progress?
What is the strategy to improve the stock price?
Why not continue the stock buyback?
TIA
Conservative, Who is more? Davenport or Interdigital. I don't hear an aggressive strategy from IDCC. Unfortunately, I can't attend the stockholder meeting, but hope someone will ask about the cash now earning 1%. I hope that there will be an announcement before then to avoid the usual non- answer.
Home | Contact Us | Careers
Clinical Trials
Business
Investor Center
2009 10-K and Proxy
News Archive
Board of Directors
Management Team
Corporate Governance
Careers
SEC Filings
Science
Therapeutic Pathways
ENMD-2076
MKC-1
ENMD-1198
Panzem®
Scientific Advisory Board
Science Archive
Clinical Trials Business Science
--------------------------------------------------------------------------------
Business
Investor Center
2009 10-K, Annual Meeting Notice and Proxy Statement
News Archive
Board of Directors
Management Team
Corporate Governance
Careers
Print This Page Email This Page Board of Directors
Michael Tarnow, Executive Chairman
Mr. Tarnow was appointed Chairman of our Board in February 2003 and was appointed Executive Chairman on February 2, 2009. Since 1995, Mr. Tarnow has been an advisor to and member of the boards of directors of several healthcare-related organizations in the U.S., Canada and Europe. He also serves on the Boards of the University of Illinois College of Law, Massachusetts College of Art Foundation and the Food Drug Law Institute. From 1995-2000, he was President and CEO of Boston-based Creative BioMolecules, Inc. Prior to that, he spent 22 years at Merck & Co., Inc., where he served in a wide variety of positions including heading corporate development, President and CEO of Merck Frosst Canada and Executive Vice President of Merck-Medco.
Dwight L. Bush, Sr., Vice Chairman
Mr. Bush has been a Director of the Company since June 2004. Mr. Bush is currently Managing Director of D.L. Bush & Associates, a Washington, DC-based financial advisory and business consulting firm. Mr. Bush was previously President & CEO of Urban Trust Bank, Urban Trust Holdings and President of UTB Education Finance, LLC from 2006 through 2007. From 2002-2006, Mr. Bush was a principal in an Arlington-based investment firm and prior to that served in various financial and management roles in financial institutions. Mr. Bush currently serves on the Board of Trustees of Cornell University, the GAVI Fund, and The National Symphony Orchestra.
Donald S. Brooks
Mr. Brooks has been a Director of the Company since April 1996 and was Vice President, Legal Affairs of the Company from 1998 until August 2001. Between 2001 and 2004, Mr. Brooks served as a consultant to the Company. Prior to that, Mr. Brooks was a practicing attorney and was previously employed by Merck & Co., Inc. for 27 years in various business and legal capacities. He currently serves as a member of the Board of Directors of BioDiem, Ltd., an Australian biotechnology company. In addition, he recently served as a director of Xenon Pharmaceuticals, Inc., a Canadian biotechnology firm, and currently acts as a consultant to that company.
Jennie Hunter-Cevera, PhD
Dr. Hunter-Cevera has been a Director of the Company since June 2001. Dr. Hunter-Cevera is the President of the University of Maryland Biotechnology Institute. Prior to joining the University of Maryland in October 1999, Dr. Hunter-Cevera had been the head of the Center for Environmental Biotechnology at Lawrence Berkeley National Laboratory between November 1994 and October 1999, Director of Fermentation, Research and Development at Cetus Corporation and a scientist at E.R. Squibb and Company. She was co-founder of The Biotic Network and Blue Sky Laboratories in Sonora, CA. Dr. Hunter-Cevera was elected to the American Academy of Microbiology in 1995, the recipient of the 1996 SIM Charles Porter Award, elected as a SIM Fellow in 1997 and the 1999 Nath Lecturer at West Virginia University. She is the 2004 recipient of the ASM Porter Award for achievement in biodiversity research and was elected as an AAAS fellow in 2007.
Peter S. Knight
Mr. Knight has been a Director of the Company since June 2000. Mr. Knight has been President of Generation Investment Management US, a London-based asset management company, since August 2004. From 2001-2003, he was a Managing Director of MetWest Financial. Prior to that, Mr. Knight’s business experience included serving as general counsel of Medicis Pharmaceutical and a practicing attorney. Mr. Knight’s experience also includes serving as chief of staff to Al Gore when Mr. Gore was a member of the U.S. House of Representatives and later the U.S. Senate and holding senior positions with four presidential campaigns, including serving as campaign manager for the successful 1996 re-election of President Clinton. Mr. Knight currently serves as a director of Medicis Pharmaceutical Corp. and Par Pharmaceuticals. He is also a director of Schroders’ mutual fund and hedge fund family, a member of the Cornell University College of Arts and Sciences Advisory Council, and the Johnson School Center for Sustainable Global Enterprise.
Mark C. M. Randall
Mr. Randall has been a Director of the Company since April 1996. He has been CEO of Commander Asset Management Ltd. since May 2002. Prior to this appointment, he was associated with Sarasin International Securities Limited, a wholly owned subsidiary of Bank Sarasin and Cie, a private bank based in Switzerland, where he was a director and later a managing director.
Committee Membership
Michael M. Tarnow (4)
Dwight L. Bush (4)(5)
Donald S. Brooks (2)
Jennie C. Hunter-Cevera, PhD (3)(4)
Peter S. Knight(1)(2)(7)
Mark C. M. Randall(1)(1)
(1) Member of the Audit Committee
(2) Member of the Compensation Committee
(3) Member of the Nominating and Corporate Governance Committee
(4) Member of Executive Committee
(5) Chairman of the Audit Committee
(6) Chairman of the Compensation Committee
(7) Chairman of the Nominating and Corporate Governance Committee
Directors
Michael Tarnow
Dwight L. Bush, Sr.
Donald S. Brooks
Jennie Hunter-Cevera, PhD
Peter S. Knight
Mark C. M. Randall
--------------------------------------------------------------------------------
Panzem® is a registered trademark of EntreMed, Inc.Terms and Conditions Copyright © 2010, EntreMed, Inc.
The Celgene Head of Research is an observer and not a regular member of the BOD as I understood Tarnow's remarks. Celgene has an important interest in ENMD 2076 because it is a potential threat to their mutiple myeloma franchise, which is the backbone of Celgene. The upside of other cancer treatments would be the icing on the cake. In my opinion Celgene could not allow any other Pharma to preempt their franchise with 2076. That is why I think they would be foolish take any risk waiting for Phase 2 results before gaining control of ENMD even at an elevated price.
endu, That is not saying much, but thank you. The problem is that big Pharma is fighting NIH and I don't mean the National Institute of Health.
Why doesn't Pfizer or Novartis offer $2 a share for 30% of the outstanding shares? That is a bargain for a discovery drug with outstanding promise in ovarian cancer, multiple myeloma, and leukemia. They spend that much on their own candidates which don't even get to Phase 2. Then, Celgene would compete with them for control and funding phase 3 clinical studies. If the big pharmas wait for phase 2 results, it will cost much, much more.
I would sell them 30% of my shares and hold the rest for the big payoff. What do you people think?
If you are a bullish investor in ENMD it is because you hope that ENMD can help people suffering from cancer resulting in a large increase in the stock price from 63 cents. If you are badmouthing IDCC you hope that they will fail and your short sale will result in a maximum gain of 63 cents. Their aspirations are not admirable and can not be very profitable. In fact, their highly leveraged positions may prove to be downright dangerous to their finances.
Does this explain the numerous ugly and bearish rants on Yahoo?
May 12 (Bloomberg) -- Nokia Oyj has chosen Anssi Vanjoki, an outspoken executive who produced its last hit smartphone three years ago, to bring back the buzz.
Vanjoki, a 20-year company veteran named yesterday to take over a new smartphone unit, launched the N95 model in March 2007. That was eclipsed three months later by Apple Inc.’s iPhone. Espoo, Finland-based Nokia, the world’s largest handset maker, still hasn’t developed a phone with the same cachet
Maybe this guy would rather settle and use our IPR to succeed than continue the old Nokia approach and lose.
bulldzr, Sounds promising.
Thanks
Google Android is getting a great deal of press. I am sorry to say that I am confused by all the talk about Sprint, Verizon and Sony Ericsson. Will IDCC benefit from it? How? TIA
george, Are you sure that Revlimid came from ENMD? It has been my impression that Celgene did the chemical research on Thalidomide that resulted in Revlimid. I enjoy your DD on ENMD and have high hopes.
IDCC is still authorized to buy back the major part of $100 million they didn't use. Why don't they buy back a part of it? Please ask at the annual meeting because I can't attend. $10-20 million will not change their major strategies.but would do a lot for shareholders. Any thoughts?
50,000K equals 50 Million. You are out of my league. LOL
Why didn't Celgene loan ENMD a paltry $3 million under some condition that didn't dilute the stock? The financing looks expensive to the stockholders. Ant ideas?
IDCC is moving up without any news or hype. Marvelous change from the past. Finally, some investors are recognizing the value here.
Relax and enjoy the show.
paheka, Where did you see this?
jai, Corzine put New Jersey in terrible financial shape similar to California. He could dispose of the $500 Million in a heartbeat. Forget about it!
IDCC Management, Please buy a few shares at $28. Pretty please, buy $ 300,000 worth. More, if you have a little cash available.
We are tired of being blocked at $28 by nefarious characters.
Thank you from a very, very old stockholder.
bulldzr, My other famous quote is,"Buy low and sell high!" I am waiting for IDCC to get high so I can sell.
Thanks
Free cash flow: So you focus on free cash flow. Everyone seems to have a definition of free cash flow. What's yours?
For us, it's the cash available for distribution to shareholders after all planned capital expenditures and cash taxes. Cash can be used to pay dividends, make share repurchases, pay down debt, make acquisitions and to invest in new internal capital projects.
What is the IDCC strategy? None of the above? As shareholders, aren't we entitled to know?
The sky is falling. Sell IDCC at $28 or for whatever those genial market makers will give you. There is no hope. The Mayans predict the end of the world in 2012.
However, on Monday after option expiration buy IDCC. It has lots of cash, high earnings, great technology, and a bright future. Forget the Mayans, they couldn't save their a**es.
The "bad guys" are keeping up their selling in order to discourage the "good guys". That's right, this is a morality play. They know that selling begets selling and it appears that they have deep pockets. I have trouble understanding how they make money out of this. I have never understood the option business but I presume they make money selling calls. Why they pick on IDCC with all its positives continues to mystify me. I have to give them credit because they are good at what they do. I still wish that KOP would dedicate $100 million to get them out of our hair.
What is the barrier at $28. I suggest that IDCC instruct their broker to buy every thing on offer at this price. This would scare the shorts and we could move on to a reasonable price. Why not?
Do you think 200 shares would cause a buying panic at Goldman Sachs?
What do think would happen if all the people who claim to be bulls on this stock bought 100 shares. Maybe, there aren't so many. On the other hand could it scare the shorts? What do you think?
Houston, We have lift-off! In a mixed metaphor, remember Elmore Leonard's famous book, " Get Shorty"
Houston, We have lift-off! In a mixed metaphor, remember Elmore Leonard's famous book, " Get Shorty"
Why do you think Nasgovitz wanted the poison pill removed? He is an investor and believes it would generate a higher price for IDCC. Remember the stock buy back is still in effect. How many catalysts do you want?
Why does $26 seem to be a barrier to higher prices for IDCC? Is there a malign genius in the basement selling at $26 so he or she can get rich. Any ideas?
The catalyst for a breakout is the balance of the stock buy back program. The volume of trading is low and the potential is great to move the stock up at low cost. A higher stock price makes acquisitions of new technology or companies attractive. JMHO
The stock buy back appears to be finished. IDCC only used 1/4 the allocated $100 million and I guess that they will not continue it. So what is the plan for the cash hoard? Is it an acquisition? Nasgovitz will grill Merritt about it tomorrow.
Bill Nasgovitz will ask tough questions tomorrow. Bill Merritt has to have prepared answers about the poison pill, new stock buyback, lack of new licensees, and use of the cash hoard. The usual BS about economic discussions and the board considering all these options will be very disappointing. I expect some announcement tonight to forestall Nasgovitz and avoid embarrassment. I don't expect any new information to come from the conference call. JMHO
Wouldn't the 30% of outstanding shares owned by Celgene effectively block any takeover by a third party?
InterDigital will host a conference call on Thursday, February 25, 2010 at 10:00 a.m. Eastern Time to discuss its fourth quarter and full year 2009 performance and other company matters.Is the discussion of other matters planned? ie. a new , poison pill or stock purchase plan
The information that Mobery objected to appears to me to be quoted from a resume of a former Entremed employee. It is interesting because of the information about a future partner that it revealed. Good luck to all.
Nokia announced today that they will introduce an expanded line of youch screen cell phones. Can anyone explain how their advanced 3G phones can avoid Interdigital IPR? Are we on the verge of a licensing agreement or a new ITC suit? TIA
buying or selling? TIA